Merck KGaA Announces Restructuring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck KGaA Announces Restructuring


ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck KGaA announced measures intended to reduce costs and increase efficiency to ensure the long-term success of its business model. The measures announced this week are part of a comprehensive transformation program that will be implemented in two phases. In the first two years, Merck plans to implement a new leadership organization, implement efficiency measures, and develop a long-term growth strategy. In the second phase, the company will explore new areas for growth. Cost savings from the first-phase efficiency measures are expected to fuel second-phase growth.

The announcement this week marks the beginning of the efficiency measures. At the beginning of 2012, Merck began the implementation of the new leadership organization, which defines the relationship of businesses, group functions, and country organizations. According to the press release, the objective of the new leadership organization is to streamline the organizational structure to be leaner, easier to navigate, and to speed up decision-making processes. The organizational realignment will continue in parallel to and support the efficiency program as well as the development of Merck’s long-term growth strategy.

The company expects the efficiency measures to result in workforce reductions across all businesses and regions, according to the release. The company deliberately did not release figures related to expected headcount reductions. In the release, Karl-Ludwig Kley, chairman of the executive board says, “We have a view on what needs to be achieved, but we will consult with the employee representatives on a country-by-country basis and we will consider any pragmatic proposals. We have specifically not published potential figures related to the efficiency program as we are committed to engaging constructively with the relevant stakeholders to achieve a mutually acceptable solution.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
100%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
0%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Key Ways for Ensuring Global Regulatory Compliance
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here